Asahi Kasei Pharma to Sponsor Research for Drug Discovery Research and Tech- nology: Open Innovation 2023

INDUSTRY.co.id - Düsseldorf, New York and Tokyo, 13 October 2022 – Asahi Kasei Pharma, subsidiary of diversified Japanese multinational company Asahi Kasei, is publicly calling for new proposals for drug development research as part of its efforts for open innovation to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes and enterprises around the world.

The application period begins on 5:00 a.m. GMT at January 5, 2023, and ends at 8:00 a.m. GMT on February 28, 2023.

Asahi Kasei Pharma established its Open Innovation Department in October 2016 with the mission to further strengthen and enhance global licensing and alliance-building activities and has since funded around 5 proposals per year on average with a total of over 20 funded proposals for state-of-the-art pharmaceutical drug developments as well as collected a wealth of creative new ideas.

The Open In- novation team is seeking to fund innovative proposals from researchers around the world for up to US$200,000 per year, per project for this upcoming round in 2023. Asahi Kasei Pharma will then pursue joint research opportunities with the drug discovery researchers together with their parent institutions in hopes to create new innovative drugs for diseases that currently have unmet needs or pioneer new platform technologies for drug discovery.

Asahi Kasei Pharma has demonstrated a successful track record in developing new drugs in the realms of autoimmune, renal, neurological, and bone disease, so the organization can provide the greatest contribution from correlating research areas and subjects.

"Asahi Kasei Pharma believes that nobody should have to give up what they would like to do because of illness," said Osamu Matsuzaki, Primary Executive Officer and Head of R&D and Business Develop- ment at Asahi Kasei Pharma.

“We believe great science comes from working together, and we are excited for the opportunity to accomplish this mission with researchers all over the world.”

Open Innovation works to establish research collaborations related to innovative drug targets and can- didate drug compounds up to the preclinical stage as well as advanced drug discovery technologies. Advancements in exploring a new mechanism of action for treating refractory autoimmune disease is one of the most promising outcomes of the research so far, with many more on the horizon. Asahi Kasei believes that these continued efforts to advance drug discovery and research technology will further contribute to life and living for people around the world.

Outline of the call for proposals Target applicants:

Researchers at universities, research institutes, and enterprises outside Japan (researchers based in Japan should refer to the Japanese website)

Research areas and subjects:

 

5. Platform technologies for drug discovery - drug formulation, analysis methods and organic syn- thesis

Funding:

Up to US$200,000 per year for each selected proposal

Research period:

1-3 years (milestones will be set for each year, and the content of the research will be reviewed as needed based on the research results)

Submissions will be assessed with respect to their potential as concepts for collaborative research and fostering of research. Further information is available on Asahi Kasei Pharma’s Open Innovation web- site.

About Asahi Kasei Pharma

In accordance with the mission, “to sincerely care for each individual life and solve their unmet medical needs with a wealth of ideas and solid science,” Asahi Kasei Pharma operates pharmaceutical and diagnostic businesses in the Health Care Sector of the Asahi Kasei Group. Asahi Kasei Pharma has developed numerous innovative drugs in the fields of immunology, neurology, critical care, musculo- skeletal disorders, and other rare diseases, contributing to society by providing highly innovative medi- cations to patients who suffer from diseases with previously unmet needs.